BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 25473830)

  • 1. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.
    Liachko NF; McMillan PJ; Strovas TJ; Loomis E; Greenup L; Murrell JR; Ghetti B; Raskind MA; Montine TJ; Bird TD; Leverenz JB; Kraemer BC
    PLoS Genet; 2014 Dec; 10(12):e1004803. PubMed ID: 25473830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration.
    Taylor LM; McMillan PJ; Liachko NF; Strovas TJ; Ghetti B; Bird TD; Keene CD; Kraemer BC
    Mol Neurodegener; 2018 Feb; 13(1):7. PubMed ID: 29409526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau-tubulin kinase 1 phosphorylates TDP-43 at disease-relevant sites and exacerbates TDP-43 pathology.
    Tian Y; Wang Y; Jablonski AM; Hu Y; Sugam JA; Koglin M; Stachel SJ; Zhou H; Uslaner JM; Parmentier-Batteur S
    Neurobiol Dis; 2021 Dec; 161():105548. PubMed ID: 34752923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tau tubulin kinases in proteinopathy.
    Taylor LM; McMillan PJ; Kraemer BC; Liachko NF
    FEBS J; 2019 Jul; 286(13):2434-2446. PubMed ID: 31034749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adult onset pan-neuronal human tau tubulin kinase 1 expression causes severe cerebellar neurodegeneration in mice.
    McMillan P; Wheeler J; Gatlin RE; Taylor L; Strovas T; Baum M; Bird TD; Latimer C; Keene CD; Kraemer BC; Liachko NF
    Acta Neuropathol Commun; 2020 Nov; 8(1):200. PubMed ID: 33228809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration.
    Wils H; Kleinberger G; Janssens J; Pereson S; Joris G; Cuijt I; Smits V; Ceuterick-de Groote C; Van Broeckhoven C; Kumar-Singh S
    Proc Natl Acad Sci U S A; 2010 Feb; 107(8):3858-63. PubMed ID: 20133711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
    Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
    Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis.
    Tan RH; Yang Y; Kim WS; Dobson-Stone C; Kwok JB; Kiernan MC; Halliday GM
    Acta Neuropathol Commun; 2017 Oct; 5(1):76. PubMed ID: 29078806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) patients.
    Collins M; Riascos D; Kovalik T; An J; Krupa K; Krupa K; Hood BL; Conrads TP; Renton AE; Traynor BJ; Bowser R
    Acta Neuropathol; 2012 Nov; 124(5):717-32. PubMed ID: 22993125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.
    Liachko NF; McMillan PJ; Guthrie CR; Bird TD; Leverenz JB; Kraemer BC
    Ann Neurol; 2013 Jul; 74(1):39-52. PubMed ID: 23424178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TDP-43 is consistently co-localized with ubiquitinated inclusions in sporadic and Guam amyotrophic lateral sclerosis but not in familial amyotrophic lateral sclerosis with and without SOD1 mutations.
    Maekawa S; Leigh PN; King A; Jones E; Steele JC; Bodi I; Shaw CE; Hortobagyi T; Al-Sarraj S
    Neuropathology; 2009 Dec; 29(6):672-83. PubMed ID: 19496940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Dissection of TDP-43 as a Leading Cause of ALS/FTLD.
    Tamaki Y; Urushitani M
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular neuropathology of TDP-43 proteinopathies.
    Neumann M
    Int J Mol Sci; 2009 Jan; 10(1):232-246. PubMed ID: 19333444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration.
    Takeda T
    Neuropathology; 2018 Feb; 38(1):72-81. PubMed ID: 28960544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracellular dynamics of Ataxin-2 in the human brains with normal and frontotemporal lobar degeneration with TDP-43 inclusions.
    Watanabe R; Higashi S; Nonaka T; Kawakami I; Oshima K; Niizato K; Akiyama H; Yoshida M; Hasegawa M; Arai T
    Acta Neuropathol Commun; 2020 Oct; 8(1):176. PubMed ID: 33115537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders.
    Hortobágyi T; Troakes C; Nishimura AL; Vance C; van Swieten JC; Seelaar H; King A; Al-Sarraj S; Rogelj B; Shaw CE
    Acta Neuropathol; 2011 Apr; 121(4):519-27. PubMed ID: 21360076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of novel Cell Division Cycle Kinase 7 inhibitors on TDP-43-related pathogenesis such as Frontotemporal Lobar Degeneration (FTLD) and amyotrophic lateral sclerosis (ALS).
    Vaca G; Martinez-Gonzalez L; Fernandez A; Rojas-Prats E; Porras G; Cuevas EP; Gil C; Martinez A; Martin-Requero Á
    J Neurochem; 2021 Feb; 156(3):379-390. PubMed ID: 32628315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylated TDP-43 becomes resistant to cleavage by calpain: A regulatory role for phosphorylation in TDP-43 pathology of ALS/FTLD.
    Yamashita T; Teramoto S; Kwak S
    Neurosci Res; 2016 Jun; 107():63-9. PubMed ID: 26723245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of TDP-43 phosphorylation in aging and disease.
    Eck RJ; Kraemer BC; Liachko NF
    Geroscience; 2021 Aug; 43(4):1605-1614. PubMed ID: 34032984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profilin-1 mutations are rare in patients with amyotrophic lateral sclerosis and frontotemporal dementia.
    van Blitterswijk M; Baker MC; Bieniek KF; Knopman DS; Josephs KA; Boeve B; Caselli R; Wszolek ZK; Petersen R; Graff-Radford NR; Boylan KB; Dickson DW; Rademakers R
    Amyotroph Lateral Scler Frontotemporal Degener; 2013 Sep; 14(5-6):463-9. PubMed ID: 23634771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.